Literature DB >> 53656

Treatment of osteoporosis of ageing with 1alpha-hydroxycholecalciferol.

B Lund, L Hjorth, I Kjaer, I Reimann, T Friis, R B Andersen, O H Sorensen.   

Abstract

Seven patients with osteoporosis of ageing were treated with synthetic 1alpha-hydroxycholecalciferol (1alpha-H.C.C.) for 3-4 months. The compound was given at a daily oral dose of 2 mug together with an oral supplement of 1 g of calcium. Clinically there was a striking improvement in the patients' physical fitness. Increased bone formation and mineralisation were seen on iliac-crest bone biopsy, and this was supported by an increased osteoblastic activity demonstrated by histochemical measurement of alkaline-phosphatase activity. Bone histology furthermore showed a reduced bone resorption, which was supported by a reduced urinary excretion of total hydroxyproline. Photon absorptiometry of the forearm accorded with the histological findings, showing a significant increase in the bone mineral content. Serum-calcium rose in all patients, one developing a severe transitory hypercalcaemia. The urinary excretion of calcium and magnesium increased significantly. The serum concentrations of 25-hydroxycholecalciferol and parathyroid hormone were not significantly affected by the treatment. It is concluded that 1alpha-H.C.C. is an effective tool in the treatment of senile osteoporosis.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 53656     DOI: 10.1016/s0140-6736(75)92656-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  8 in total

1.  Contrasting effects on bone formation and on fracture healing of cholecalciferol and of 1 alpha-hydroxycholecalciferol.

Authors:  S Dekel; A Ornoy; E Sekeles; D Noff; S Edelstein
Journal:  Calcif Tissue Int       Date:  1979-11-06       Impact factor: 4.333

2.  Bone disease in the elderly.

Authors:  R Smith
Journal:  Proc R Soc Med       Date:  1976-12

3.  Effect of 1 alpha-hydroxycholecalciferol on psoriasis vulgaris: a pilot study.

Authors:  S Takamoto; T Onishi; S Morimoto; S Imanaka; S Yukawa; T Kozuka; Y Kitano; Y Seino; Y Kumahara
Journal:  Calcif Tissue Int       Date:  1986-12       Impact factor: 4.333

4.  Vitamin D metabolism and the response to 1,25-dihydroxycholecalciferol in osteoporosis.

Authors:  M Davies; E B Mawer; P H Adams
Journal:  Calcif Tissue Res       Date:  1977-05

5.  Serum vitamin D metabolites in younger and elderly postmenopausal women.

Authors:  C Christiansen; P Rødbro
Journal:  Calcif Tissue Int       Date:  1984-01       Impact factor: 4.333

6.  Diagnosis and management of involutional osteoporosis.

Authors:  P M Hodsman
Journal:  Can Fam Physician       Date:  1979-04       Impact factor: 3.275

7.  25-Hydroxycholecalciferol in experimental osteoporosis.

Authors:  M Carrozzo; R Pallante; F P Cantatore; F Lo Sasso; M D'Amore; V Pipitone
Journal:  Clin Rheumatol       Date:  1985-09       Impact factor: 2.980

8.  Whole-body in-vivo neutron activation analysis in assessing treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.

Authors:  R B Naik; P Gosling; C P Price; B H Robinson; J T Dabek; D A Heath; H M James; J A Kanis; R Smith
Journal:  Br Med J       Date:  1976-07-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.